Taizhou Tiande Pharmaceutical

Taizhou Tiande Pharmaceutical is a clinical-stage biopharmaceutical company based in Taizhou, China, specializing in the development of innovative peptide therapeutics for metabolic and endocrine disorders. The company's lead candidate, Tidaglutide (TD-001), is a long-acting glucagon-like peptide 1 (GLP-1) receptor agonist currently in clinical development for the treatment of type 2 diabetes and obesity. Taizhou Tiande leverages a proprietary peptide modification platform to enhance the half-life and efficacy of its drug candidates. Operating within the China Medical City (CMC) hub, the company focuses on providing high-quality, cost-effective treatments for chronic diseases prevalent in the Chinese market. Its research and development efforts are centered on addressing the growing global demand for advanced metabolic therapies.